The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Aydan Huseynov - Ladenburg Thalmann & Co. Inc. - Analyst
: Hi, good afternoon, everyone. Linda, AJ, thank you very much for providing updates on the quarter. I have a couple of questions. First, I wanted to
start from industry-wide question. I think very soon, probably tomorrow, there will be Sarepta's AdCom meeting about the DMD gene therapy.
So my question is, do you think there will be any read-across, any spillover effects regarding how we should think about the FDA regulatory path
for DMD therapies in general, and how this may affect the CAP-1002?
Question: Aydan Huseynov - Ladenburg Thalmann & Co. Inc. - Analyst
: Thank you, Linda. Appreciate your thoughts. Very helpful. And regarding the breakdown, so I know that you enroll both ambulatory and
non-ambulatory patients. Could you provide an update how many you enrolled so far as of today, if you could share that? And is there any way to
understand what's the ratio of ambulatory versus non-ambulatory patients so far?
Question: Aydan Huseynov - Ladenburg Thalmann & Co. Inc. - Analyst
: Yeah. Yeah, thank you. Yeah, that makes sense in the clinical endpoints, that eventually what is going to matter rather than microdystrophin
production. Maybe if you could share, is there any updates on European partnerships, and does Nippon Shinyaku have any appetites to market
CAP-1002 in Europe?
Question: Aydan Huseynov - Ladenburg Thalmann & Co. Inc. - Analyst
: Okay. All right. And the last from me, I'm trying to understand. So are you planning to have any product or indication that you would commercialize
on your own without a partner? So if yes, what would that be, product or indication?
Question: Aydan Huseynov - Ladenburg Thalmann & Co. Inc. - Analyst
: Okay, Makes sense. Thanks so much for taking my questions. Thank you.
|
